Stilwill Sarah E, Cooper Brian C
Department of Obstetrics and Gynecology, University of Vermont College of Medicine, Burlington, USA.
J Reprod Med. 2007 Oct;52(10):979-80.
Endometrial hyperplasia in patients with a history of breast cancer presents a therapeutic dilemma. The standard conservative therapy for hyperplasia, high-dose progestins, is contraindicated in breast cancer. Anastrozole, an aromatase inhibitor, is becoming first-line adjuvant therapy for breast cancer in postmenopausal women and may have protective effects on the endometrium.
A 51-year-old, obese woman with a history of breast cancer presented with a 2-day history of heavy postmenopausal bleeding. Endometrial biopsy demonstrated simple hyperplasia without cellular atypia. After consultation with the patient's oncologist, the patient received adjuvant anastrozole therapy for the breast cancer; it led to resolution of the endometrial hyperplasia.
Adjuvant therapy with anastrozole may be beneficial in resolving endometrial hyperplasia in patients with breast cancer.
有乳腺癌病史的患者发生子宫内膜增生会带来治疗难题。增生的标准保守治疗方法是大剂量孕激素，但这在乳腺癌患者中是禁忌的。阿那曲唑，一种芳香化酶抑制剂，正成为绝经后女性乳腺癌的一线辅助治疗药物，并且可能对子宫内膜有保护作用。
一名51岁肥胖女性，有乳腺癌病史，出现绝经后大量出血2天。子宫内膜活检显示为单纯性增生，无细胞异型性。在与患者的肿瘤学家会诊后，患者接受了乳腺癌辅助阿那曲唑治疗；这使得子宫内膜增生得到缓解。
阿那曲唑辅助治疗可能有助于解决乳腺癌患者的子宫内膜增生问题。
Zotero 插件